Navigation Links
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Date:3/12/2008

INDIANAPOLIS, March 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY), strongly disagrees with the characterization of company practices as alleged by the Connecticut Attorney General Richard Blumenthal in a news release issued March 11, 2008.

The tone and content of the release is a disservice to patients who may currently be taking Zyprexa to treat a life-threatening disease. Specifically, the news release contained no acknowledgement of the seriousness of schizophrenia or bipolar disorder, no reference to the importance of treatment stability, and provided no guidance to patients who may now have questions about their treatment.

Given the lack of complete information in the news release, Lilly offers the following:

-- Patients should continue with medications that have been prescribed and

discuss their concerns with their doctor.

-- Patients can get information about Zyprexa by contacting the

LillyAnswers Center at 1-800-LillyRx (1-800-545-5979) or going to the

Zyprexa website at http://www.zyprexa.com.

Zyprexa is a lifesaving medication that has been taken by more than 23 million people worldwide. We remain confident in the safety and efficacy of Zyprexa based on the depth and breadth of scientific research conducted around the world.

Lilly is committed to the highest ethical standards and to promoting our medications only for approved uses. We have clear guidelines and extensive training for our sales representatives to help assure that they provide appropriate promotional information that is within the scope of prescribing information approved by the FDA.

We believe these claims are without merit and we will vigorously defend against them.

Zyprexa Background

Zyprexa is indicated in the United States for the short- and long-term treatment of schizophrenia, acute mixed and manic episodes of bipolar I disorder, and maintenance treatment of bipolar disorder. Since Zyprexa was introduced in 1996, it has been prescribed to approximately 23 million people worldwide. Zyprexa is not approved for patients under 18 years of age.

Zyprexa is not approved for the treatment of patients with dementia-

--------------------------------------------------------------------

related psychosis. Elderly patients with dementia-related psychosis

--------------------------------------------------------------------

treated with atypical antipsychotic drugs are at an increased risk of

--------------------------------------------------------------------

death compared with those patients taking a placebo.

----------------------------------------------------

In addition, compared to elderly patients with dementia-related psychosis taking a placebo, there was a significantly higher incidence of cerebrovascular adverse events in elderly patients with dementia-related psychosis treated with Zyprexa.

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including Zyprexa.

While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to fall on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics. Physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or who have borderline increased blood glucose level. Patients taking olanzapine should be monitored regularly for worsening of glucose control. Persons with risk factors for diabetes who are starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing.

Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using olanzapine, is advised. Significant, and sometimes very high, elevations in triglyceride levels have been observed with olanzapine use. Modest mean increases in total cholesterol have also been seen with olanzapine use.

Potential consequences of weight gain should be considered prior to starting olanzapine. Patients receiving olanzapine should receive regular monitoring of weight.

As with all antipsychotic medications, a rare and potentially fatal condition known as NMS has been reported with Zyprexa. If signs and symptoms appear, immediate discontinuation is recommended. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Other potentially serious adverse events include low blood pressure, seizures, elevated prolactin levels, elevated liver enzymes, cognitive and motor impairment, body temperature elevation, and trouble swallowing.

The most common treatment-emergent adverse event associated with Zyprexa in placebo-controlled, short-term schizophrenia and bipolar mania trials was somnolence. Other common events were dizziness, weight gain, personality disorder (COSTART term for nonaggressive objectionable behavior), constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia, increased appetite and tremor.

Full prescribing information, including a boxed warning, is available at http://www.zyprexa.com.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

Zyprexa(R) (olanzapine, Lilly)

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
2. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
3. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
7. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
10. Lilly Receives NCQA Design Certification for Depression Care Management Program
11. Lilly and Glenmark Pharmaceuticals Announce License Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... FRANCISCO , February 28, 2017 The global  pulse ... a new report by Grand View Research, Inc. The pulse oximeters market is ... to the growing prevalence of target diseases such as chronic obstructive pulmonary disease ... Continue Reading ... Grand View Research ...
(Date:2/28/2017)... , Feb 28, 2017 Nordic Nanovector ASA (OSE: ... 2016. A presentation of the results by the company,s senior management ... Oslo - details below. ... 2016 was a very successful year for ... development of Betalutin®, progressed with our preclinical candidates and build the ...
(Date:2/27/2017)... Ga., Feb. 27, 2017 Halyard Health, Inc. (NYSE: ... 2016 results and provided its 2017 outlook and related key ... sales were $410 million, a 2 percent increase compared to ... fourth quarter 2016 was $10 million compared to net income ... quarter adjusted net income was $24 million compared to adjusted ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... BrightStar Care Marietta announced that it has received ... Pulse. This award is granted only to top-ranking home care providers, based on client ... ranked among home care providers from across the country who have proven their ability ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Much attention ... concern for women who become dependent on opioid painkillers has fallen short. From 1999 ... compared to a 237% increase in fatal overdoses in male populations.(1) , The proportion ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... Vancouver, BC (PRWEB) , ... February 27, 2017 ... ... top drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at ... (RMT) to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment ...
Breaking Medicine News(10 mins):